Expertise in
22
conditions

Dr. Eila C. Skinner

Urology
300 Pasteur Dr, 
Stanford, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
22
conditions
300 Pasteur Dr, 
Stanford, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Eila Skinner is an Urologist in Stanford, California. Dr. Skinner is highly rated in 22 conditions, according to our data. Her top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy.

Her clinical research consists of co-authoring 96 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Urology
Licenses
Urology in CA
Hospital Affiliations
Stanford Health Care
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Health Plan of San Mateo
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

STANFORD HEALTH CARE
300 Pasteur Dr, Stanford, CA 94305

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-Unresponsive, BCG-RelaPsing, and High-Risk BCG-Naive Non-muscle Invasive UroThelial Carcinoma of the BLADDER
PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-Unresponsive, BCG-RelaPsing, and High-Risk BCG-Naive Non-muscle Invasive UroThelial Carcinoma of the BLADDER
Enrollment Status: Recruiting
Publish Date: January 30, 2025
Intervention Type: Other, Radiation, Biological, Drug
Study Drugs: Bacillus of Calmette-Guerin, Durvalumab
Study Phase: Phase 1/Phase 2
Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)
Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Procedure, Other
Study Phase: Not Applicable
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Biological, Other
Study Drugs: Bacillus of Calmette-Guerin, Bacillus of Calmette-Guerin Tokyo-172 Strain Solution, Bacillus of Calmette-Guerin Tokyo-172 Strain Vaccine
Study Phase: Phase 3
A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer
A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
View 5 Less Clinical Trials

96 Total Publications

Differences in postoperative communication patterns among patients with limited English proficiency following radical cystectomy for bladder cancer.
Differences in postoperative communication patterns among patients with limited English proficiency following radical cystectomy for bladder cancer.
Journal: Urologic oncology
Published: May 13, 2025
Similar Doctors
Expertise in
13
conditions
Dr. Geoffrey A. Sonn
Urology | General Surgery
Expertise in
13
conditions
Dr. Geoffrey A. Sonn
Urology | General Surgery

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Geoffrey Sonn is an Urologist and a General Surgeon in Stanford, California. Dr. Sonn is highly rated in 13 conditions, according to our data. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Nephrectomy, and Reconstructive Urology Surgery.

Expertise in
19
conditions
Dr. Simon L. Conti
Urology | General Surgery
Expertise in
19
conditions
Dr. Simon L. Conti
Urology | General Surgery

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Simon Conti is an Urologist and a General Surgeon in Stanford, California. Dr. Conti has been practicing medicine for over 16 years is highly rated in 19 conditions, according to our data. His top areas of expertise are Kidney Stones, Obstructive Uropathy, Hydronephrosis, Ureteroscopy, and Lithotripsy.

Expertise in
31
conditions
Dr. Marshall L. Stoller
Urology
Expertise in
31
conditions
Dr. Marshall L. Stoller
Urology

Ucsf Medical Group Business Services

400 Parnassus Ave, 
San Francisco, CA 
 (27.6 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Marshall Stoller is an Urologist in San Francisco, California. Dr. Stoller is highly rated in 31 conditions, according to our data. His top areas of expertise are Kidney Stones, Cystinuria, Hydronephrosis, Ureteroscopy, and Lithotripsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Skinner's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile